Key Takeaways
- Lundbeck's foundation ownership enables CEO van Zyl to prioritize long-term R&D investment in precision neurology despite looming patent cliffs.
- The $2.6bn Longboard acquisition secures bexicaserin (patent protection until 2041) as a critical growth bridge beyond Rexulti's 2029 patent expiry.
- Van Zyl has transformed Lundbeck's pipeline from predominantly early-stage assets to four Phase III programs by 2026, balancing current performance with future growth potential.
Amid an industry-wide scramble to secure growth beyond looming patent cliffs, Denmark’s Lundbeck is undergoing a strategic transformation under CEO Charl van Zyl
“We are a company that’s revitalizing and reinventing ourselves,” van Zyl told In Vivo
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?